Antibodies
4 September 2023
Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 531 August 2023
Alpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)30 August 2023
InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC29 August 2023
AbbVie Submits Regulatory Applications to FDA and EMA for Risankizumab (SKYRIZI®) in Ulcerative Colitis29 August 2023
Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors29 August 2023
ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan23 August 2023
TechBio Innovator Etcembly Reveals World’s First Generative AI-designed Bispecific T Cell Engager With Picomolar Affinity23 August 2023
Vincerx Pharma Announces FDA Clearance of IND for VIP94323 August 2023
Anti-CD20 Monoclonal Antibody Rituxan® Approved for Lupus Nephritis that has Not Responded Sufficiently to Existing Therapies22 August 2023
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody19 August 2023
BITT Announces FDA Acceptance of IND for TNFR2 AntibodyNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports